Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests

Table 3 Metastatic breast cancer: economic cost of inaccurate HER2 immunohistochemical test results. Based on FN and FP test results (Nordic Immunohistochemistry Quality Control Group data), US treatment costs, US patient numbers and US productivity data; weighted according to the estimated prevalence of immunohistochemistry

	Metastatic breast cancer
Outcome, US $	Approved IVD	Laboratory-developed IVD	Difference
Direct cost/patient	176	1228	1052
Total direct costs^a	859 446	5 992 471	5 133 025
Cost of lost productivity/patient^b	52	120	68
Total cost of lost productivity^c	255 594	586 221	330 627

IVD in vitro diagnostic
^aCosts corrected for the prevalence of IHC 2+ tumours [19]. ^bProductivity loss per year per patient undergoing a HER2 test. ^cCost for the annual number of new patients undergoing a HER2 test and receiving systemic treatment in the USA

ISSN: 1472-6963